A950220 Stock Overview
A clinical-stage T cell-focused biotech company, develops and sells immuno-therapeutics.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
NeoImmuneTech, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | ₩1,475.00 |
52 Week High | ₩2,195.00 |
52 Week Low | ₩1,180.00 |
Beta | 0.86 |
11 Month Change | -1.34% |
3 Month Change | -25.20% |
1 Year Change | -33.41% |
33 Year Change | -85.75% |
5 Year Change | n/a |
Change since IPO | -89.72% |
Recent News & Updates
Companies Like NeoImmuneTech (KOSDAQ:950220) Could Be Quite Risky
Aug 13Will NeoImmuneTech (KOSDAQ:950220) Spend Its Cash Wisely?
Mar 22Shareholder Returns
A950220 | KR Biotechs | KR Market | |
---|---|---|---|
7D | 9.9% | 14.5% | 7.9% |
1Y | -33.4% | 30.5% | -0.5% |
Return vs Industry: A950220 underperformed the KR Biotechs industry which returned 30.5% over the past year.
Return vs Market: A950220 underperformed the KR Market which returned -0.5% over the past year.
Price Volatility
A950220 volatility | |
---|---|
A950220 Average Weekly Movement | 6.2% |
Biotechs Industry Average Movement | 9.4% |
Market Average Movement | 6.4% |
10% most volatile stocks in KR Market | 11.9% |
10% least volatile stocks in KR Market | 3.4% |
Stable Share Price: A950220's share price has been volatile over the past 3 months.
Volatility Over Time: A950220's weekly volatility (6%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2014 | 90 | Luke Yun Oh | www.neoimmunetech.com |
NeoImmuneTech, Inc., a clinical-stage T cell-focused biotech company, develops and sells immuno-therapeutics. It is developing NT-I7, a clinical-stage long-acting human IL-7 for oncologic and infectious diseases. The company was incorporated in 2014 and is headquartered in Rockville, Maryland.
NeoImmuneTech, Inc. Fundamentals Summary
A950220 fundamental statistics | |
---|---|
Market cap | ₩29.17b |
Earnings (TTM) | -₩52.98b |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.6x
P/E RatioIs A950220 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
A950220 income statement (TTM) | |
---|---|
Revenue | ₩0 |
Cost of Revenue | ₩0 |
Gross Profit | ₩0 |
Other Expenses | ₩52.98b |
Earnings | -₩52.98b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -2.68k |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0% |
How did A950220 perform over the long term?
See historical performance and comparison